Rotavirus Infections

On the whole, Beyfortus generated 547 million euros (about $592 million) for all of 2023, reaching 410 million euros in the second quarter of its launch. As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial immunization rollout with partner AstraZeneca. On both fronts, Sanofi expects to see dividends in 2024. Last year represented a "pivotal" stretch for the drugmaker, one in which the French pharma largely proved its thesis that it can become a global immunology powerhouse, CEO Paul Hudson said on a call with investors Thursday. Separately, Sanofi's AZ-partnered respiratory syncytial virus (RSV) antibody Beyfortus pulled down 547 million euros (about $592 million) during its first year on the market, a figure Sanofi expects to roughly double this year. The partners have been hamstrung on Beyfortus supply since last fall, and it will take plenty more manufacturing work before the antibody is available fully unfettered, execs explained. “Clearly, Sanofi and AstraZeneca are working very hard to extend [Beyfortus’] manufacturing network,” which includes packaging and filling sites, Sanofi’s vaccine chief Thomas Triomphe explained on the company’s earnings call. Many of those production lines still need to be cleared by regulatory authorities around the world, he added. “That’s the work that is ongoing right now in order to be able to completely ‘de-bottleneck’ the supply and have the full supply for season 2025,” Triomphe said. Supply should increase in 2024, Triomphe stressed, and Sanofi still expects Beyfortus to breach the blockbuster threshold ($1 billion) this year. While Sanofi expects some RSV sales in the first half of 2024, the third and fourth quarters will be “key” for Beyfortus revenues this year, Triomphe said. So far, Beyfortus' uptake in the U.S. has surpassed previous childhood immunization benchmarks, such as those for rotavirus and pneumococcal disease, according to the company. Sanofi has successfully delivered its antibody to a “broad infant population,” reaching some 35% of young patients in the U.S. and France and a whopping 90% in Spain, Triomphe said. On the flip side, Sanofi’s influenza vaccine business was down 4%, clocking 741 million euros ($802 million) last year, courtesy of dropping immunization rates and increased competition in the U.S., Triomphe explained. All told, the immunization arm of Sanofi snared 2 billion euros ($2.2 billion) for the latest 12-month period, an 8.3% increase. Elsewhere, Sanofi's Regeneron-partnered immunology superstar Dupixent was no slouch last year, either. The drug generated around 10.7 billion euros ($11.6 billion) in 2023, growing 34% across the globe. For 2024, Sanofi expects Dupixent to bring home roughly 13 billion euros in sales, with much of that boost being driven by an expected approval and launch in chronic obstructive pulmonary disease during the second half of the year. Sanofi is becoming a “launch engine,” Hudson said. In fact, Sanofi’s new roster of drugs Beyfortus, Altuviiio and Tzield reeled in an impressive 731 million euros for all of last year, which “exceeded” the company’s expectations, according to the CEO. Besides its launch efforts, Sanofi is rolling out a series of savings initiatives in a bid to save upward of 2 billion euros from 2024 to the end of 2025. The company will implement measures such as pipeline reallocation, "smart spending" and changes to country setups. Beyond Dupixent’s 13 billion euro sales goal, Sanofi expects vaccine sales writ large to grow in the mid single digits this year. In contrast, the company is expecting to take a hit in the first half of 2024 thanks to Aubagio’s loss of exclusivity. That drug’s plunge off the patent cliff represents Sanofi’s “last major [loss of exclusivity]” for the rest of the decade, Hudson said. Overall, Sanofi’s full-year sales for 2024 clocked in at 43.07 billion euros, growing 5.3% over the sum the company generated in 2023.

NEW YORK--( BUSINESS WIRE )-- DocGo Inc . (Nasdaq:DCGO), a leading provider of technology-enabled mobile health services, today announced the expansion of its vaccination and public health initiatives in Arizona through a new contract with the Department of Health in Santa Cruz County, Arizona. Beginning in late November, DocGo now operates a mobile clinic to enhance vaccine accessibility in a rural area with limited access to medical resources. Santa Cruz County is designated as a medically underserved area by the Arizona Department of Health Services. This new Santa Cruz clinic expands vaccination access in the county. “By expanding our partnership with the Department of Health in Santa Cruz County, we are not only bringing crucial medical services directly to residents, but also addressing the pressing issue of primary healthcare shortages in rural communities,” said Lee Bienstock, CEO of DocGo. “This initiative is another step in the right direction as we empower communities and make healthcare a tangible reality for every individual, as we work to bridge the healthcare gap in Santa Cruz County.” While rural communities only account for 14 percent of the U.S. population, rural communities represent nearly two-thirds of primary healthcare shortage areas. According to University of Arizona Center for Rural Health, the state currently has a shortage of 560 primary care physicians – particularly affecting Arizona’s rural counties. DocGo previously offered flu and COVID vaccines in mobile clinics with Santa Cruz County Health Department, as well as with the Maricopa County Health Department and the state of Arizona Department of Health. The new clinic is equipped to provide a broader range of vaccines, including Varicella (Chickenpox), MMR (Measles, Mumps, Rubella), DTap (Diphtheria, tetanus, pertussis), Tdap, Hib, Hep A, Hep B, HPV, Influenza, Meningococcal, IPV (Polio), Rotavirus, Pneumococcal, Tetanus, COVID. The clinic launched on November 20, 2023 and operates four days a week, eight hours a day at the County Health Department Office, which is located at 275 Rio Rico Dr., Rio Rico Arizona 85648. About DocGo DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo disrupts the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's proprietary, AI-powered technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit docgo.com . Forward-Looking Statements This announcement contains forward-looking statements (including within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and Section 27A of the U.S. Securities Act of 1933, as amended) concerning DocGo. These statements include, but are not limited to, statements that address our expected future business, financial performance and guidance and statements about (i) our plans, objectives and intentions with respect to future operations, services and products, including our transition to non-COVID related services, geographic expansion, rapid normalization initiative, new and existing contracts and backlog, serviceable patient population, M&A activity, workforce growth, leadership transition, cash position and share repurchase program, (ii) our competitive position and opportunities, including our addressable market opportunities, expected demand for our products and our ability to realize the benefits from our operating model, and (iii) other statements identified by words such as "may", "will", "expect", "intend", "plan", "potential", "believe", "seek", "could", "estimate", "judgment", "targeting", "should", "anticipate", "predict" "project", "aim", "goal", "outlook", "guidance", “design” and similar words, phrases or expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as assumptions made by, and information currently available to, management, and current market trends and conditions. Forward-looking statements inherently involve risks and uncertainties, many of which are beyond our control, and which may cause actual results to differ materially from those contained in our forward-looking statements. Accordingly, you should not place undue reliance on such statements. Particular uncertainties that could materially affect current or future results include possible accounting adjustments made in the process of finalizing reported financial results; any risks associated with global macroeconomic and geopolitical conditions and concerns, including rising interest rates, the inflationary environment, the potential recessionary environment, regional conflict and tensions, financial institution instability and the prospect of a shutdown of the U.S. federal government; the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the COVID-19 coronavirus pandemic; competitive pressures; availability of healthcare professionals; changes in the cost of labor; pricing declines; rates of growth in our target markets; our ability to improve gross margins; cost-containment measures; loss of major customers; legislative and regulatory actions; the impact of legal proceedings and compliance risks; the impact on our business and reputation in the event of information technology system failures, network disruptions, cyber-attacks, or losses or unauthorized access to, or release of, confidential information; and the ability of the Company to comply with laws and regulations regarding data privacy and protection. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise.

ATLANTA, Nov. 12, 2023 /PRNewswire/ -- Nobel Prize Winner Katalin Karikó, PhD, and former Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, MD (RADM, USPHS, RET), today received the 2023 Fries Prize for Improving Health. Karikó was honored for persevering through years of challenges to pioneer work in advancing the mRNA platform, the discovery of which has changed the vaccine field. Schuchat was honored for turning science into impact by preventing infant deaths due to Group B Streptococcal (GBS) disease and saving millions of lives through extraordinary public health leadership. To combat the COVID-19 pandemic it took the work of Dr. Karikó and her research partner developing the mRNA technology. Dr. Schuchat along with her public health colleagues developed strategies and programs to protect people from a broad range of vaccine-preventable and other infectious diseases including COVID-19. Former CDC Director and public health legend Dr. Bill Foege once said the best vaccine won't work unless you get shots in arms. The Fries Prize for Improving Health award was presented this morning at the American Public Health Association's (APHA) annual meeting, which is taking place in Atlanta. The award recognizes an individual or organization making major contributions to the improvement of public health with emphasis on recent contributions to health. It is intended for those who have done the most to improve health for the greatest number of people. This is the first time in the more than 30-year history of the award that two individuals simultaneously received this recognition. The monetary award for the Fries Prize for Improving Health is $70,000, which will be divided between the recipients. "Drs. Karikó and Schuchat exemplify the true meaning of the Fries Prize for Improving Health—doing the most good for the most people," said Judy Monroe, MD, president and CEO of the CDC Foundation. "These two leaders in their respective fields show how medicine and public health can work together to save countless lives. They are both truly inspiring, and I'm grateful for their selfless contributions." Karikó, biochemist and researcher best known for her contributions to mRNA technology, was awarded the 2023 Nobel Prize in Physiology or Medicine. Karikó and her research partner, Drew Weissman, MD, PhD, with whom she shares the Nobel Prize, laid the foundation for the COVID-19 vaccines. Karikó is a professor at the University of Szeged and adjunct professor at the Perelman School of Medicine, University of Pennsylvania, where she has worked for 24 years. For four decades, her research has focused on RNA mediated mechanisms with the ultimate goal of developing in vitro-transcribed mRNA for protein therapy. Her discovery of the mRNA technology used to rapidly develop the COVID vaccine changed the course of the COVID-19 pandemic and paved the way for mRNA treatments for a large number of other acute and chronic diseases. "Through her creative thinking, brilliance, persistence and absolute dedication, Dr. Karikó has made historic contributions that have not only saved countless millions of lives from SARS-CoV2 but have also led to a new approach for treating devastating diseases," stated Jean Bennett, MD, PhD, professor emeritus, Ophthalmology and Cell & Developmental Biology and co-director, Center for Advanced Retinal and Ocular Therapeutics, University of Pennsylvania Perelman School of Medicine, who provided a letter of recommendation for Karikó. Schuchat's career with CDC has spanned more than 33 years. Her roles included principal deputy director, acting CDC director, director of CDC's National Center for Immunization and Respiratory Diseases (NCIRD), chief of the Respiratory Diseases branch and Epidemic Intelligence Service officer. Throughout her public health career, Schuchat dedicated herself to ensuring every person has the opportunity for good health. Schuchat played key roles in CDC emergency responses including the recent COVID-19 pandemic, the 2019 outbreak of E-cigarette or Vaping-associated Lung Injuries, the 2009 H1N1 pandemic influenza response, the 2003 SARS outbreak in Beijing and the 2001 bioterrorist anthrax response. Globally, she has worked on meningitis, pneumonia and Ebola vaccine trials in West Africa, conducted surveillance and prevention projects in South Africa, and served on the board of GAVI, the Vaccine Alliance. Schuchat is credited with saving thousands of babies in the United States by preventing neonatal Group B Streptococcal disease. During the decade she led the NCIRD, Schuchat emphasized tools for improved communications with parents to sustain childhood immunizations and supported the introduction of several new vaccines in the United States and around the world. "Dr. Schuchat represents the best of public health—science-based, results oriented, committed to public service in usual and challenging times and responsible for preventing millions of deaths worldwide," stated Claire Broome, MD, assistant surgeon general US Public Health Service (retired), who nominated Schuchat for the Fries Prize. The James F. and Sarah T. Fries Foundation is a nonprofit corporation incorporated in 1991. The mission of the foundation is to identify and honor individuals, organizations or institutions that have made great contributions to the health of the public. The foundation seeks to reward accomplishment rather than promise, practicality rather than theory. The CDC Foundation is honored to partner with the James F. and Sarah T. Fries Foundation, which established and funds the award. As of 2016, the CDC Foundation manages and administers the Fries Foundation's public health award programs, which include the Fries Prize for Improving Health and the Elizabeth Fries Health Education Award. About the CDC Foundation The CDC Foundation helps the Centers for Disease Control and Prevention (CDC) save and improve lives by unleashing the power of collaboration between CDC, philanthropies, corporations, organizations and individuals to protect the health, safety and security of America and the world. The CDC Foundation is the go-to nonprofit authorized by Congress to mobilize philanthropic partners and private-sector resources to support CDC's critical health protection mission. Since 1995, the CDC Foundation has raised over $2 billion and launched more than 1,300 programs impacting a variety of health threats from chronic disease conditions including cardiovascular disease and cancer, to infectious diseases like rotavirus and HIV, to emergency responses, including COVID-19 and Ebola. The CDC Foundation managed hundreds of CDC-led programs in the United States and in more than 90 countries last year. Learn more at . SOURCE CDC Foundation